{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"10"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"42"},{"groupId":"OG001","value":"42"},{"groupId":"OG002","value":"60"}],"units":"Participants"}],"description":"Related Adverse Event is any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a investigational product and related to the investigational product.","groups":[{"description":"Patients with the following types of soft tissue sarcoma: leiomyosarcoma, poorly differentiated/de-differentiated liposarcoma, high grade pleomorphic undifferentiated sarcoma/MFH, MPNST and synovial sarcoma). Pembrolizumab was administered at 200 mg intravenously every 3 weeks\n\nPembrolizumab","id":"OG000","title":"Soft Tissue Sarcoma"},{"description":"Patients with the following types of bone sarcoma: Ewing sarcoma, osteosarcoma, and chondrosarcoma \\[de-differentiated or mesenchymal\\]. Pembrolizumab was administered at 200 mg intravenously every 3 weeks\n\nPembrolizumab","id":"OG001","title":"Bone Sarcoma"},{"description":"Patients with the following types of soft tissue sarcoma: poorly differentiated/de-differentiated liposarcoma, high grade pleomorphic undifferentiated sarcoma. Pembrolizumab was administered at 200 mg intravenously every 3 weeks","id":"OG002","title":"Expansion Cohort"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Up to 5 years","title":"Adverse Events Related to Pembrolizumab Treatment in Patients With Advanced Sarcoma, by Patient","type":"SECONDARY","unitOfMeasure":"Grade 3 or higher treatment related AEs"}